J&J’s one-shot Covid vaccine is safe and generates promising immune response in early trial
|Johnson & Johnson’s one-dose Covid vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to early trial data.
The one-shot COVID vaccine, known as Ad26.COV2.S, is reportedly safe according to a Phase I and II study that shows the vaccine gives antibodies.
Market implications
Good news such as this will underpin the optimism for an economic recovery, supporting US stocks.
Shares are up 1.7% in J&J on the news.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.